NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Valuation Check As New Prostate Cancer Therapy Data Progresses
Johnson & Johnson (JNJ) is back in focus after releasing preliminary Phase 1b data on pasritamig plus docetaxel in metastatic castration-resistant prostate cancer, showing high PSA response rates and a safety profile aligned with docetaxel alone.
See our latest analysis for Johnson & Johnson.
At a share price of $248.56, Johnson & Johnson has seen a 30-day share price return of 9.38% and a year to date share price return of 19.87%. Its 1-year total shareholder return of 52.73% and 3-year...